baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LONZA N/ CH0013841017 /

30/08/2024 17:31:58	Chg. +0.80	Volume	Bid18:11:03	Ask18:11:03	Market Capitalization	Dividend Y.	P/E Ratio
555.60CHF	+0.14%	357,301 Turnover: 198.39 mill.	550.00Bid Size: 35	560.00Ask Size: 160	41.37 bill.CHF	0.72%	62.57

GlobeNewswire 08/08 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 06/08 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 14/06 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 13/06 Repligen Announces CEO Transition Plan

GlobeNewswire 30/05 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 15/05 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 08/05 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/05 Maravai LifeSciences Reports First Quarter 2024 Financial Results

GlobeNewswire 04/04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 04/04 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 27/02 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 15/02 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 04/01 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 19/12/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 09/12/2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 07/12/2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 07/12/2023 Business Update

GlobeNewswire 06/11/2023 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 01/11/2023 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO

GlobeNewswire 19/10/2023 Viralgen welcomes back Andy Holt as CCO

GlobeNewswire 16/10/2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...

GlobeNewswire 02/10/2023 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

GlobeNewswire 20/09/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

GlobeNewswire 19/09/2023 Galapagos appoints Simon Sturge to its Board of Directors

GlobeNewswire 13/09/2023 Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer

LONZA N/ CH0013841017 /

If you wish to receive reply to your feedback, please provide your email address.